tbuckley/cabot-search huggingface dataset:
THU0477 Does fibromyalgia affect physical activity of the patients?
Authors: M Alkan Melikoglu, S Dogantekin
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Fibromyalgia syndrome (FMS) as a chronic pain condition can cause impaired physical activity level of the patients. <h3>Objectives</h3> The purpose this case-control study was to evaluate the physical activity levels of patients with FMS and to assess a possible relation between physical activity and disease characteristics. <h3>Methods</h3> Seventy patients with FMS and 50 age-gender matched controls were included in the study. The demographic features and duration of symptoms of the participants were recorded. The level of pain was evaluated using the visual analogue scale (VAS). The Fibromyalgia Impact Questionnaire (FIQ) scoring system was used for the evaluation of the impact of FMS. Also for assessing the physical activity in our participants, we used The International Physical Activity Questionnaire (IPAQ). Mann–Whitney U and Pearson correlation tests were used for group comparisons and was used for correlation analyses. <h3>Results</h3> The mean age of the patients and healthy controls were 41,90±8,53 years and 41,52±9,01 years, respectively. Symptom duration of the patients was 61,0±45,8 months. The patients with FMS presented significantly less transportation-related, recreational and total physical activity levels, besides reporting significantly less time spent walking and less time spent in vigorous activities than healthy controls (p&lt;0,05). Also, in patients with FMS, there was a negative correlation between pain and the scores of self-reported moderate or vigorous physical activity (r =- 0.41, p&lt;0.01). However, we couldn9t find any correlation between FIQ and IPAQ scores. <h3>Conclusions</h3> Patients with FMS are physically less active than healthy individuals of similar profile. This reduced activity seems to be associated with pain, but not with the impact of the disorder. In the approach to the patient with FMS, considering the patient9s physical activity behavior can contribute to the management of the disorder. In future studies assessing the effect of exercise in FMS, consideration of the patients9 physical activity level may contribute to a complete evaluation of the patients. <h3>Disclosure of Interest</h3> None declared
SP0070 News from omeract – imaging and more
Authors: V Strand
Journal: Annals of the Rheumatic Diseases (2017)

Objective In rheumatoid arthritis (RA), MRI provides earlier detection of structural damage than radiography (X-ray) and more sensitive detection of intra-articular inflammation than clinical examination. This analysis was designed to evaluate the ability of early MRI findings to predict subsequent structural damage by X-ray. Methods Pooled data from four randomised controlled trials (RCTs) involving 1022 RA hands and wrists in early and established RA were analysed. X-rays were scored using van der Heijde-modified or Genant-modified Sharp methods. MRIs were scored using Outcome Measures in Rheumatology (OMERACT) RA MRI Score (RAMRIS). Data were analysed at the patient level using multivariable logistic regression and receiver operating characteristic curve analyses. Results Progression of MRI erosion scores at Weeks 12 and 24 predicted progression of X-ray erosions at Weeks 24 and 52, with areas under the curve (AUCs) of 0.64 and 0.74, respectively. 12-week and 24-week changes in MRI osteitis scores were similarly predictive of 24- week and 52-week X-ray erosion progressions; pooled AUCs were 0.78 and 0.77, respectively. MRI changes in synovitis at Weeks 12 and 24 also predicted progression of X-ray joint damage (erosion and joint-spacenarrowing) at Weeks 24 and 52 (AUCs=0.72 and 0.65, respectively). Conclusions Early changes in joint damage and inflammation detected with MRI predict changes in joint damage evident on subsequent X-rays. These findings support the use of MRI as a valid method for monitoring structural damage in short-duration RCTs. <h3>Disclosure of Interest</h3> None declared
Uncovering burden disparity: A comparative analysis of the impact of moderate-to-severe psoriasis and hidradenitis suppurativa
Authors: Iltefat H. Hamzavi, Murali Sundaram, Cynthia Nicholson, Marko Zivkovic, Angela Parks-Miller, Jianyi Lee, Jingbo Yi, Yihua Gu, Martin M. Okun, Arijit Ganguli, Steve R. Arikian
Journal: Journal of the American Academy of Dermatology (2017)
FRI0587 Different factors are related to recurrence of existing organ involvement and new development of organ involvement in igg4-related disease
Authors: I Mizushima, S Tsuge, Y Fujisawa, S Hara, F Suzuki, K Ito, H Fujii, K Yamada, M Kawano
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> IgG4-related disease (IgG4-RD) is a recently recognized systemic inflammatory disorder that can affect many organs [1]. In IgG4-RD, relapse including recurrence of existing organ involvement (REOI) and new development of organ involvement (NDOI) easily occurs during the clinical course, and its predictors have been suggested [2, 3]. However, differences between risk factors of REOI and those of NDOI have not been clarified. <h3>Objectives</h3> This study aimed to clarify the respective risk factors of REOI and NDOI in IgG4-RD. <h3>Methods</h3> We retrospectively investigated factors related to REOI and NDOI in 86 IgG4-RD patients whose follow-up period was more than 12 months. For assessment of factors related to REOI and NDOI, we performed uni- and multivariate Cox regression analysis. On stepwise multivariate analysis, we applied the variables with <i>P</i>&lt;0.1 in univariate analysis and the predictors of relapse suggested in past reports (age, sex, serum IgG4, IgG, and IgE levels, eosinophil counts, and RF positivity) [2, 3], and used the forward selection method (including factors presenting with <i>P</i>&lt;0.05). <h3>Results</h3> The patients comprised 57 men and 29 women (mean age 65.9 years). Mean follow-up period was 63.1 months (range 14–150). At diagnosis, their mean serum IgG4 level was 718 mg/dL (range 10.7–3,610). Seventy-one patients were treated with glucocorticoid (GC). REOI was detected at 52.3 months (range 1.0–120) after the diagnosis in 20 patients, including 4 not receiving GC at that time. On the other hand, NDOI was detected at 37.6 months (range 5.0–120) after the diagnosis in 15 patients, including 8 not receiving GC then. In multivariate Cox regression analysis, blood eosinophil counts [per 100/μL, hazard ratio (HR) 1.072, 95% confidence interval (CI) 1.018–1.129, <i>P</i>=0.008] and continuation of GC (vs discontinuation or observation without GC, HR 0.245, 95% CI 0.076–0.793, <i>P</i>=0.019) had a significant impact on the time to NDOI, whereas age (per year, HR 0.942, 95% CI 0.899–0.986, <i>P</i>=0.011) and ANA positivity (vs negativity, HR 6.632, 95% CI 1.892–23.255, <i>P</i>=0.003) had a significant impact on the time to REOI. <h3>Conclusions</h3> The present study suggests that the risk factors of REOI and NDOI in IgG4-RD are different. <h3>References</h3> Stone JH et al. IgG4-related disease. N Engl J Med. 2012 Feb 9;366(6):539–51. Yamamoto M et al. Identification of relapse predictors in IgG4-related disease using multivariate analysis of clinical data at the first visit and initial treatment. Rheumatology (Oxford). 2015 Jan;54(1):45–9. Wallace ZS et al. Predictors of disease relapse in IgG4-related disease following rituximab. Rheumatology (Oxford). 2016 Jun;55(6):1000–8. <h3>Disclosure of Interest</h3> None declared
Hypertrophic Obstructive Cardiomyopathy
Authors: Rick A. Nishimura, Hubert Seggewiss, Hartzell V. Schaff
Journal: Circulation Research (2017)

Hypertrophic cardiomyopathy is a genetic disorder characterized by marked hypertrophy of the myocardium. It is frequently accompanied by dynamic left ventricular outflow tract obstruction and symptoms of dyspnea, angina, and syncope. The initial therapy for symptomatic patients with obstruction is medical therapy with β-blockers and calcium antagonists. However, there remain a subset of patients who have continued severe symptoms, which are unresponsive to medical therapy. These patients can be treated with septal reduction therapy, either surgical septal myectomy or alcohol septal ablation. When performed by experienced operators working in high-volume centers, septal myectomy is highly effective with a &gt;90% relief of obstruction and improvement in symptoms. The perioperative mortality rate for isolated septal myectomy in most centers is &lt;1%. Alcohol septal ablation is a less invasive treatment. In many patients, the hemodynamic and clinical results are comparable to that of septal myectomy. However, the results of alcohol septal ablation are dependent on the septal perforator artery supplying the area of the contact between the hypertrophied septum and the anterior leaflet of the mitral valve. There are some patients, particularly younger patients with severe hypertrophy, who do not uniformly experience complete relief of obstruction and symptoms. Both techniques of septal reduction therapy are highly operator dependent. The final decision as to which approach should be selected in any given patient is dependent up patient preference and the availability and experience of the operator and institution at which the patient is being treated.
Lower-extremity symmetry influences knee abduction moments during sidestepping in rugby
Authors: Scott Randall Brown
Journal: British Journal of Sports Medicine (2017)

I (1) identified laboratory-based tools to assess a surrogate measure of anterior cruciate ligament (ACL) injury risk (knee abduction (valgus) moment), (2) assessed differences between positions and legs following a theoretical model of injury risk factors and (3) outlined a new framework for assessing rugby athletes to help guide the progression of individualised training strategies.

ACL injuries can be devastating for rugby athletes given their substantial time loss from the sport.1 2 These potentially career-ending injuries often occur during sidestepping.3 Consequences of ACL injury can lead to reinjury and/or injury to the opposite (healthy) leg.4 Mechanical differences within the musculoskeletal system (ie, strength, balance, power5) between the two legs (asymmetry) may be a precursor to injury.6 There is currently little known regarding how much asymmetry is ‘normal’ in uninjured rugby athletes. Individualised multifactorial assessments can inform practitioners of what ‘normal’ levels of asymmetry consist of, help guide them with the performance enhancement or return-to-sport process and further educate them on interventions to decrease the risk of reinjury.5 …
Intramuscular tendon involvement on MRI has limited value for predicting time to return to play following acute hamstring injury
Authors: Anne D van der Made, Emad Almusa, Rod Whiteley, Bruce Hamilton, Cristiano Eirale, Frank van Hellemondt, Johannes L Tol
Journal: British Journal of Sports Medicine (2017)

Background Hamstring injury with intramuscular tendon involvement is regarded as a serious injury with a delay in return to play (RTP) of more than 50 days and reinjury rates up to 63%. However, this reputation is based on retrospective case series with high risk of bias. Objective Determine whether intramuscular tendon involvement is associated with delayed RTP and elevated rates of reinjury. Methods MRI of male athletes with an acute hamstring injury was obtained within 5 days of injury. Evaluation included standardised MRI scoring and scoring of intramuscular tendon involvement. Time to RTP and reinjury rate were prospectively recorded. Results Out of 70 included participants, intramuscular tendon disruption was present in 29 (41.4%) injuries. Injuries without intramuscular tendon disruption had a mean time to RTP of 22.2±7.4 days. Injuries with &lt;50%, 50%–99% and 100% disruption of tendon cross-sectional area had a mean time to RTP of 24.0±9.7, 25.3±8.6 and 31.6±10.9 days, respectively. Injuries with full-thickness disruption took longer to RTP compared with injuries without disruption (p=0.025). Longitudinal intramuscular tendon disruption was not significantly associated with time to RTP. Waviness was present in 17 (24.3%) injuries. Mean time to RTP for injuries without and with waviness was 22.6±7.5 and 30.2±10.8 days (p=0.014). There were 11 (15.7%) reinjuries within 12 months, five (17.2%) in the group with intramuscular tendon disruption and six (14.6%) in the group without intramuscular tendon disruption. Conclusion Time to RTP for injuries with full-thickness disruption of the intramuscular tendon and waviness is significantly longer (by slightly more than 1 week) compared with injuries without intramuscular tendon involvement. However, due to the considerable overlap in time to RTP between groups with and without intramuscular tendon involvement, its clinical significance for the individual athlete is limited.
SP0038 How to assess cartilage in ra and pitfalls + demo
Authors: P Mandl
Journal: Annals of the Rheumatic Diseases (2017)

Cartilage damage is a key process in rheumatoid arthritis which appears to be more clearly associated with irreversible physical disability than bony damage. While conventional radiography only allows the evaluation of joint space narrowing, a proxy measure of cartilage loss, musculoskeletal ultrasound is a reliable tool for evaluating cartilage damage. The presentation will introduce the pitfalls and challenges associated with visualizing cartilage in rheumatic diseases in general and rheumatoid arthritis in particular. It will also review recent studies in the filed which have validated sonography for both the quantitative measurement of cartilage thickness and for the semiquantitative scoring of cartilage change. A practical demonstration will also be provided. <h3>Disclosure of Interest</h3> None declared
AB0250 The adipose tissue as predictive factor of disease activity in rheumatoid arthritis patients: evaluation of body fat composition by bioelectrical impedance analysis and ultrasonography
Authors: MG Anelli, C Rotondo, R Fanizzi, O Magazzino, M Giannotta, M Giannini, O Lorusso, E Praino, MT Viggiani, F Cacciapaglia, M Barone, G Lapadula, F Iannone
Journal: Annals of the Rheumatic Diseases (2017)

with two recommended DMARDS Grade IV: single use of DMARDS including MTX less than 5mg.Results: There was no relationship between titers of Anti-CCP Ab and titers of RF.We found significant statistical correlation between anti-CCP antibody titers and inflammatory markers such as CRP and MMP-3.There was significant statistical correlation between CRP and MMP-3.In terms of treatment intensity, strong intensity group showed high titer of anti-CCP Ab and CRP.Titer of RF and MMP-3 level did not have any relationship with the treatment intensity.In cases treated with biologics, anti-CCP Ab and CRP were significantly higher compared to non-biologic case group.In 80% of cases treated with biologics titer of anti-CCP was more than 200 units.However, non-biologic treatment was continued in more than 50% of cases with anti-CCP Ab higher than 200 units.Conclusions: Even though we treated cases based on the severity of the symptoms of the patient and response in laboratory data, high anti-CCP Ab titers and CRP at the base line were most associated with the treatment intensity after 1 year.The results of our study suggest that the titer of anti-CCP Ab can be better a predictor of the treatment intensity than MMP-3 and RF.
FRI0567 Differences in adcherence to osteoporosis medications in patients with rheumatic diseases: a 3-year retrospective cohort study
Authors: O Nikitinskaya, N Toroptsova
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Patients with rheumatic diseases (RD) have an increased risk of developing osteoporosis (OP) compared with healthy population due to chronic inflammation, low physical activity and using some kind of medications. Persons with RD and OP require prolonged osteoporosis treatment due to increased risk of fracture. <h3>Objectives</h3> To evaluate adherence and persistence with different osteoporosis medications in RD patients with OP during 3 years. <h3>Methods</h3> We conducted a retrospective study of 204 patients (82% women, mean age 54±11 years) with RD (93 – rheumatoid arthritis, 48 – systemic sclerosis, 39 – systemic lupus erythematosus and 24 – ankylosing spondylitis), whom OP was diagnosed in 2013. In 2016 we revised there medical charts for collection information on the osteoporosis treatment and performed telephone contact for patient9s self-reporting. <h3>Results</h3> 196 (96%) patients started the OP treatment. Among them 26% - alendronate, 24% received alfacalcidol or supplements of calcium and vitamin D only, 16% - stroncium ranelate, 12% - ibandronate, 9% zoledronic acid, 8% - calcitonin and 5% - denosumab. 8 (4%) patients didn9t start the drug treatment at all, 72 (35%) patients were persisted less than 12 months, 47 (23%) – 2 years and 77 (38%) – 3 years. Mean persistence was 2.1, 2.4, 1.6, 1.7, 1.9, 2.0 years for alendronate, alfacalcidol, stroncium ranelate, ibandronate, zoledronic acid, denosumab, respectively. 61 (31%) persons were switched from one antiosteoporotic medication to another due to side effects, inconvenient dose regimen or other reasons. Persistence to oral therapy was better among women than men (p&lt;0.05), especially on daily regimen. Discontinuers were less likely than persistent subjects to visit rheumatologist and BMD measurement each year for control of treatment (p&lt;0.05). Patients with ankylosing spondylitis were less persistent than persons with other RD. Presence of OP fractures in anamnesis had no significant influence on adherence. 8 (4%) patients had fractures during retrospective period, among them 6 - received only supplements of calcium and vitamin D, 1 - zoledronic acid once and 1 – without OP therapy. <h3>Conclusions</h3> Only 1/3 of patients with RD received antiosteoporotic drugs during 3 years. Visits to rheumatologist and BMD measurements increased subject9s persistence. Improving the quality of medical care can be achieved through education and motivation of patients for a long-term treatment of OP. <h3>Disclosure of Interest</h3> None declared
Patterns of Sedentary Behavior and Mortality in U.S. Middle-Aged and Older Adults
Authors: Keith M. Diaz, Virginia J. Howard, Brent Hutto, Natalie Colabianchi, John E. Vena, Monika M. Safford, Steven N. Blair, Steven P. Hooker
Journal: Annals of Internal Medicine (2017)

Background: Excessive sedentary time is ubiquitous in Western societies. Previous studies have relied on self-reporting to evaluate the total volume of sedentary time as a prognostic risk factor for mortality and have not examined whether the manner in which sedentary time is accrued (in short or long bouts) carries prognostic relevance. Objective: To examine the association between objectively measured sedentary behavior (its total volume and accrual in prolonged, uninterrupted bouts) and all-cause mortality. Design: Prospective cohort study. Setting: Contiguous United States. Participants: 7985 black and white adults aged 45 years or older. Measurements: Sedentary time was measured using a hip-mounted accelerometer. Prolonged, uninterrupted sedentariness was expressed as mean sedentary bout length. Hazard ratios (HRs) were calculated comparing quartiles 2 through 4 to quartile 1 for each exposure (quartile cut points: 689.7, 746.5, and 799.4 min/d for total sedentary time; 7.7, 9.6, and 12.4 min/bout for sedentary bout duration) in models that included moderate to vigorous physical activity. Results: Over a median follow-up of 4.0 years, 340 participants died. In multivariable-adjusted models, greater total sedentary time (HR, 1.22 [95% CI, 0.74 to 2.02]; HR, 1.61 [CI, 0.99 to 2.63]; and HR, 2.63 [CI, 1.60 to 4.30]; P for trend < 0.001) and longer sedentary bout duration (HR, 1.03 [CI, 0.67 to 1.60]; HR, 1.22 [CI, 0.80 to 1.85]; and HR, 1.96 [CI, 1.31 to 2.93]; P for trend < 0.001) were both associated with a higher risk for all-cause mortality. Evaluation of their joint association showed that participants classified as high for both sedentary characteristics (high sedentary time [≥12.5 h/d] and high bout duration [≥10 min/bout]) had the greatest risk for death. Limitation: Participants may not be representative of the general U.S. population. Conclusion: Both the total volume of sedentary time and its accrual in prolonged, uninterrupted bouts are associated with all-cause mortality, suggesting that physical activity guidelines should target reducing and interrupting sedentary time to reduce risk for death. Primary Funding Source: National Institutes of Health.
Loss of Caveolin 2 in endometrial adenocarcinoma
Authors: Katherine Stagliano, Carl Morrison, Tracy Litzi, Andrew Berchuck, G. Larry Maxwell, John Risinger
Journal: Clinical Cancer Research (2007)

A46  Caveolin disregulation has been noted in several cancer types and has been implicated in suppressing tumorigenesis. Endometrial cancer gene expression microarray data has previously indicated a distinct down-regulation of Caveolins in endometrial cancers consistent with a possible tumor suppressor function. The objective of this study was to validate this observation at the protein level and to perform an initial functional examination of Caveolins and their role in suppressing endometrial cancer growth.  In order to examine possible mechanisms of Caveolin down-regulation we evaluated CAV1 and CAV2 expression in a panel of endometrial cancer cell lines. CAV1 was expressed in all five cell lines whereas CAV2 message was absent in four of five cell lines. To examine whether epigenetic modifications were involved in suppressing CAV2 message we examined CAV2 levels following 5-aza-29-deoxycytidine treatment. CAV2 levels dramatically increased following treatment indicating that epigenetic modification of this locus was involved in silencing CAV2. We examined CAV1 and CAV2 levels in paraffin embedded specimens of normal and cancerous endometrium. CAV1 was expressed in normal endometrial stroma and was absent in epithelial cells. CAV2 was expressed in normal epithelial cells and absent in stroma. Endometrial cancers exhibited an almost universal loss of CAV2. Furthermore, we examined the effect of CAV2 expression on colony formation in the CAV2 null HHUA endometrial cancer cellline. CAV2 significantly inhibited colony formation in HHUA cells as compared to empty vector (negative control) and was similar to TP53 (positive control, HHUA cell are TP53 mutant).  Immunohistochemical analysis of endometrial samples confirmed loss ofCAV2 in endometrial cancer epithelial cells. CAV2 levels were readily restored in endometrial cancer cells following treatment with agents affecting methylation. Furthermore, CAV2 inhibited colony formation when restored to HHUA cells. These data support the contention that CAV2 loss is common in endometrial cancer and that loss of CAV2 is consistent with tumor suppressive ability of the gene.